Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Picankibart in the Treatment of Moderate-to-Severe Palmoplantar Pustulosis: A Prospective, Single-Arm, Open-Label Clinical Study

NCT07552454 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT07552454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07552454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Picankibart in the Treatment of Moderate-to-Severe Palmoplantar Pustulosis: A Prospective, Single-Arm, Open-Label Clinical Study
Lead sponsor
Xijing Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
April 15, 2026
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis